Strand, V., de Vlam, K., Covarrubias-Cobos, J. A., Mease, P. J., Gladman, D. D., Graham, D., . . . Hsu, M. (2019). Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open.
Chicago Style CitationStrand, Vibeke, et al. "Tofacitinib or Adalimumab Versus Placebo: Patient-reported Outcomes From OPAL Broaden—a Phase III Study of Active Psoriatic Arthritis in Patients With an Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs." RMD Open 2019.
MLA CitationStrand, Vibeke, et al. "Tofacitinib or Adalimumab Versus Placebo: Patient-reported Outcomes From OPAL Broaden—a Phase III Study of Active Psoriatic Arthritis in Patients With an Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs." RMD Open 2019.